SIGLEC9 (CN 111465614 A Biosimilar) Recombinant Monoclonal Antibody

1. The SIGLEC9 rs2075803 G/rs2258983 A haplotype, which corresponds to a Siglec-9 variant that is less effective at suppressing inflammatory response, may be a risk factor for the development of emphysema. PMID: 27878892
2. Glycophorin A, the most abundant sialoglycoprotein on erythrocytes, engaged neutrophil Siglec-9, a sialic acid-recognizing receptor known to dampen innate immune cell activation. These studies demonstrate a previously unsuspected role for erythrocytes in suppressing neutrophils ex vivo and in vitro and help explain why neutrophils become easily activated after separation from whole blood. PMID: 28416510
3. Data suggest that sialic acid-binding Ig-like lectin-9 (Siglec-9)may serve as a potential diagnostic and therapeutic target for rheumatoid arthritis (RA). PMID: 28273363
4. The mechanism of the Siglec-9 and AOC3 interaction is mediated both by protein-sugar interactions via the V domain and by the protein-protein interactions via the C22 Siglec9 domain. PMID: 27893774
5. This work defines a critical role for aberrantly glycosylated MUC1 and identifies an activating pathway that follows engagement of Siglec-9. PMID: 27595232
6. Constitutively expressed Siglec-9 inhibits LPS-induced CCR7, but enhances IL-4-induced CD200R expression in human macrophages. PMID: 26923638
7. Ligands for Siglec-8 and Siglec-9 may regulate the function of eosinophils, mast cells, neutrophils, and other cells in sinus mucosa. PMID: 26694037
8. Inflammation results in up-regulation of immuneinhibitory Siglec-8 and Siglec-9 sialoglycan ligands on human airways. PMID: 25747723
9. a polymorphism that reduced Siglec-9 binding to carcinomas was associated with improved early survival in non-small-cell lung cancer patients PMID: 25225409
10. Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3. PMID: 24882272
11. Protein degradation of focal adhesion kinase and related molecules was induced by Siglec-9 binding to its counterreceptors via sialylglycoconjugates, leading to the modulation of adhesion kinetics of cancer cells. PMID: 24145038
12. Siglec-9 expressed on immune cells may play a role as a potential counterreceptor for MUC1 and that this signaling may be another MUC1-mediated pathway and function in parallel with a growth factor-dependent pathway. PMID: 24045940
13. The Siglec-9 peptide binding to the enzymatic groove of VAP-1 can be used for imaging conditions, such as inflammation and cancer. PMID: 21821708
14. Siglec-9 A391C was the only polymorphism related to TCR-mediated signaling in human Siglec-9, resulting in less inhibition compared to the wild type. PMID: 20733319
15. These results suggest that Siglec-9 expressed on DCs is involved in immunoregulation through ligation with mucins in an epithelial cancer patient. PMID: 20971061
16. MUC16-Siglec-9 binding likely mediates inhibition of anti-tumor immune responses. PMID: 20497550
17. Septic shock patients exhibit different ex vivo death responses of blood neutrophils after Siglec-9 ligation early in shock. PMID: 19295491
18. Binding studies on recombinant human Siglec-9 show recognition of both Neu5Ac and Neu5Gc; in striking contrast, chimpanzee and gorilla Siglec-9 strongly prefer binding Neu5Gc. PMID: 14693915
19. Siglec-9 can inhibit Fc epsilon receptor I-mediated serotonin release from rat basophilic leukemia cells and recruit the tyrosine phosphatases SHP-1 and SHP-2. PMID: 15557178
20. data suggest that apoptotic (ROS- and caspase-dependent) and nonapoptotic (ROS-dependent) death pathways are initiated in neutrophils via Siglec-9 PMID: 15827126
21. Siglecs-9 did not interact with sulfate derivatives of LacNAc and sulfated oligosaccharides containing sialic acid. PMID: 16732727
22. The Siglec-9 provides not only a useful marker for certain subsets of AML, but also a potential therapeutic target. PMID: 16828866
23. These results demonstrate that Siglec-9 enhances the production of the anti-inflammatory cytokine IL-10 in macrophages. PMID: 18325328
24. A review of the cytotoxic effects of natural anti-Siglec9 autoantibodies on both neutrophils and eosinophils. PMID: 18558361
25. Increased bacterial survival are also facilitated by group b Streptococcus sialylated capsular polysaccharide interactions with Siglec-9. PMID: 19196661
26. Data suggest that age-specific interactions between Siglec-9 and SHP-1 may influence the altered inflammatory responsiveness and longevity of neonatal polymorphonuclear neutrophils. PMID: 19542910

Show More

Hide All

HGNC: 10878

OMIM: 605640

KEGG: hsa:27180

STRING: 9606.ENSP00000413861

UniGene: Hs.245828